PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
24744799-0	2014	Efficacy and Safety Profile of Combining Sorafenib with Chemotherapy in Patients with HER2-Negative Advanced Breast Cancer: A Meta-analysis.	Sorafenib	41-50	erb-b2 receptor tyrosine kinase 2	Homo sapiens	86-90	
24744799-1	2014	PURPOSE: The aim of the study was to evaluate the efficacy and safety of combining sorafenib with chemotherapy in patients with human epidermal growth factor receptor 2 (HER2)-negative advanced breast cancer.	Sorafenib	83-92	erb-b2 receptor tyrosine kinase 2	Homo sapiens	134-168	
24744799-1	2014	PURPOSE: The aim of the study was to evaluate the efficacy and safety of combining sorafenib with chemotherapy in patients with human epidermal growth factor receptor 2 (HER2)-negative advanced breast cancer.	Sorafenib	83-92	erb-b2 receptor tyrosine kinase 2	Homo sapiens	170-174	
24744799-3	2014	Randomized clinical trials that compared the efficacy and safety of sorafenib plus chemotherapy in patients with HER2-negative advanced breast cancer with placebo plus chemotherapy were eligible.	Sorafenib	68-77	erb-b2 receptor tyrosine kinase 2	Homo sapiens	113-117	
	And PUF/PDA/UNG membrane could remove MB and CR simultaneously through one-time filtration in MB/CR binary system.	Chromium	97-99	uracil DNA glycosylase	Homo sapiens	8-15